发明名称 Mitigation of contrast-induced nephropathy
摘要 A system which includes a pressurizing mechanism to pressurize a fluid including a contrast enhancement agent for delivery to a patient and a control system in operative connection with the pressurizing mechanism. The control system includes a system to adjust control of fluid injection based upon a measurement of renal function of the patient.
申请公布号 US9421330(B2) 申请公布日期 2016.08.23
申请号 US200912611172 申请日期 2009.11.03
申请人 Bayer HealthCare LLC 发明人 Kalafut John F.;Hirschman Alan D.;Griffiths David M.;Joyce Thomas P.;Stokes Jerry A.;Callan Gerald W.;Hack Dennis P.;Gulick Julie;Maihoefer Andreas R.;Uber, III Arthur E.
分类号 A61M5/172;G06F19/00;A61B5/00;A61B6/00;A61M5/142;A61B5/055;A61B5/20;A61M5/00 主分类号 A61M5/172
代理机构 代理人 Stevenson James R.;Bradley Gregory L.;Clark Bryan
主权项 1. A system comprising: a pressurizing mechanism to pressurize a fluid comprising a contrast enhancement agent for delivery to a patient; and a control system in operative connection with the pressurizing mechanism, the control system comprising: a protocol generation system to generate an initial injection protocol comprising a set of injection parameters defining a total amount of the contrast enhancement agent to be delivered to the patient according to the initial injection protocol; anda contrast induced nephropathy risk assessment system to adjust one or more of the injection parameters of the initial injection protocol based at least in part upon a measurement of renal function of the patient and an assessment of a risk of contrast induced nephropathy,wherein the assessment of the risk of contrast induced nephropathy is determined, at least in part, on an analysis of the patient's glomerular filtration rate, and wherein adjusting one or more injection parameters of the initial injection protocol comprises determining a recommended maximum amount of the contrast enhancement agent to be delivered to the patient, comparing the recommended maximum amount of the contrast enhancement agent to the total amount of the contrast enhancement agent to be delivered to the patient according to the initial injection protocol, and presenting, on a display screen associated with the system, a reduction factor by which the total amount of the contrast enhancement agent to be delivered to the patient according to the initial injection protocol should be reduced.
地址 Whippany NJ US